Tumor-specific DXR uptake was completely blocked when mice were co-injected with a 50-fold molar excess of the soluble NGR peptide (16), confirming the peptide recognizing tumor vasculature-driven cell drug binding and penetration. This evidence concerns the gene RTN4R and neoplasm.